含F／2A序列的抗P185^erbB2人鼠嵌合抗体慢病毒表达载体的构建

目的构建含F／2A序列的抗P185^erbB2人鼠嵌合抗体慢病毒表达载体,观察其在293T细胞中的表达。方法用具有自我剪切能力的弗林蛋白酶（Furin）／口蹄疫病毒2A多肽（F/2A）连接人鼠嵌合抗体的重链和轻链,形成一个开放阅读框（ORF）,插入慢病毒表达载体pWPI,构建重组抗P185神睨全长人鼠嵌合抗体表达载体pWPI／H-F2A—L。以已构建的慢病毒表达载体pWPI／H-IRES-L为对照质粒。应用磷酸钙沉淀法将慢病毒载体3质粒系统共转染入293T细胞进行包装,测定病毒滴度。再感染293T细胞,荧光显微镜下观察GFP的表达和转染效率,RT—PER、ELISA方法分别检测嵌合抗体mRNA和蛋白的表达。结果经测序鉴定,pWPI／H—F2A—L与预期设计一致;pWPI／H—F2A—L组的病毒滴度为4．3×10^5TU／ml,而pWPI／H—IRES—L组的病毒滴度为3．5×10^5TU／ml;两组重组慢病毒的转染效率分别为87．68％和79．08％;两组重组慢病毒感染293T细胞后,都有嵌合重链和嵌合轻链的表达,由F／2A介导的嵌合抗体的表达水平要高于由IRES介导的嵌合抗体。结论成功构建了含F／2A序列的抗P185^erbB2人鼠嵌合抗体慢病毒表达载体,为今后抗P185^erbB2工程抗体的研究奠定了基础。     

嵌合HCV串联多表位的乙肝S基因真核载体构建及表达

[目的]构建丙型肝炎病毒(hepatitis C virus,HCV)串联多中和抗原表位与乙型肝炎病毒(hepatitis B virus,HBV)S抗原嵌合基因真核表达质粒,并在293T细胞中进行表达。[方法]将HCV基因中高度保守且具有广谱交叉中和活性的三个表位和一个HVR1模拟表位串连。串联表位嵌合于HBV S基因的氨基端胞外区,形成嵌合基因MEpS;将基因克隆至真核表达载体pCI-neo中,构建重组质粒pCI-MEpS。将质粒转染至293T细胞中,间接免疫荧光及Western Blot检测嵌合基因的表达情况。[结果]重组质粒经双酶切证实构建正确;pCI-MEpS转染的293T细胞胞浆内可见较强的绿色荧光,Western Blot显示pCI-MEpS在相对分子量约38 kDa处可见蛋白条带。[结论]构建了HBV S抗原嵌合HCV串联多中和抗原表位的重组质粒,成功在293T细胞中表达,为制备嵌合HCV串联多中和抗原表位的HBV S抗原VLPs,研究嵌合VLPs免疫动物后产生的中和抗体的保护作用奠定了实验基础。     

密码子优化的人H5N1流感病毒HA基因在哺乳动物细胞中获得高效表达

为了提高人禽流感病毒血凝素HA的表达量,应对流感大流行疫苗的需求,按照人的偏爱密码子将H5N1(A/Anhui/1/2005)流感病毒的HA基因进行优化改造,经全基因合成后插人到真核表达载体pDC315中,构建了真核表达质粒pDC315-Mod.HA;将此质粒和含野生HA基因的真核表达质粒pDC315-Wt.HA分别转染293T细胞,比较HA蛋白的表达量.结果表明:经间接免疫荧光实验及Western blot实验比较和鉴定,密码子优化后,HA蛋白在293T细胞中的表达水平显著提高,为流感大流行疫苗的研究打下了基础.     

人自噬相关基因12真核表达载体的构建及表达

目的:构建带myc标签的自噬相关基因12(ATG12)的真核表达载体,获得myc-ATG12融合蛋白。方法:以人乳腺文库为模板,采用PCR技术扩增人ATG12编码序列,将其插入p XJ-40-myc载体构建重组质粒,转染人胚肾293T细胞,Western印迹检测表达情况;将重组质粒与ATG3表达质粒共转染293T细胞,免疫共沉淀法检测二者的相互作用。结果:myc-ATG12真核表达质粒构建成功,转染293T细胞后融合蛋白获得表达,其相对分子质量约17×103,可与Flag-ATG3结合。结论:构建并表达了带myc标签的人ATG12真核表达载体,为进一步研究ATG12在自噬中的功能奠定了基础。     

USP22基因克隆及其融合蛋白真核表达载体的构建

目的克隆人类泛素水解酶22（ubiquitin—specific processing enzyme22,USP22）基因,构建与绿色荧光蛋白融合表达的真核载体。方法利用RT—PCR技术以HeLa细胞总RNA为模板分别扩增USP22基因cDNA序列两片段,依次插入真核表达载体pEGFP—N1;重组质粒转染HEK293T细胞,观察融合蛋白表达及绿色荧光的分布。结果测序结果显示USP22序列与GenBank收录数据一致,酶切显示重组质粒pEG—FP—USP22构建无误,质粒转染后有80％左右HEK293T细胞表达绿色荧光,且在胞质与胞核中广泛分布。结论成功克隆USP22基因并构建与GFP融合表达的真核载体,为进一步深入研究USP22基因的生物学功能奠定了基础。     

人Smurf1基因真核表达质粒的构建和表达

[目的]构建人Smurf1基因的真核表达载体并检测其表达和细胞亚定位。[方法]PCR法从人胚肾细胞HEK-293T中扩增Smurf1基因的ORF序列,将其插入到带Flag标签的p CMV5真核表达载体,插入位点为限制性内切酶SalⅠ和XbaⅠ之间。酶切并测序鉴定该质粒的正确性。将成功构建的质粒Flag-Smurf1转染HEK-293T细胞和Hela细胞,Western Blotting检测Smurf1蛋白的表达情况;转染Mv. 1. Lu细胞,免疫荧光检测Smurf1蛋白在细胞中的亚定位。[结果]成功扩增出Smurf1基因的ORF序列;连入p CMV5中获得了质粒Flag-Smurf1;酶切鉴定得到2. 2 kb大小的片段,测序结果显示连入的是Smurf1基因的c DNA序列正确。Western Blotting结果显示该质粒可在HEK-293T细胞和Hela细胞中表达,表达大小约为80 k Da,符合预期。免疫荧光实验结果显示过表达的Smurf1主要定位在细胞膜上。[结论]成功构建了带Flag标签的人Smurf1基因的真核表达质粒,该质粒可在细胞中顺利表达。     

人LC3B基因的真核表达及鉴定

目的:构建带HA标签的重组人LC3B基因的真核表达载体,获得HA-LC3B融合蛋白,并初步检测其生物学功能。方法:从人乳腺文库中通过PCR技术扩增LC3B基因编码序列,将其插入pc DNA3.0-HA载体,获得HA-LC3B真核表达载体;将重组质粒与空载体分别转染人胚肾293T细胞,通过Western印迹检测转染细胞的表达情况,免疫共沉淀实验证实其生物学活性。结果:双酶切和测序结果表明HA-LC3B真核表达质粒构建成功,Western印迹表明重组质粒转染293T细胞后获得表达;免疫共沉淀实验显示HA-LC3B融合蛋白可以和Atg4B蛋白相互作用,具有较好的生物学活性。结论:在真核表达系统中表达了带HA标签的人LC3B,为进一步研究细胞自噬奠定了基础。     

人自噬相关基因5真核表达载体的构建及表达鉴定

目的:构建带Flag标签的自噬相关基因5(ATG5)的真核表达载体,获得Flag-ATG5融合蛋白。方法:以人乳腺文库为模板,采用PCR技术扩增人ATG5编码序列,将其插入pc DNA3-Flag载体,转染人胚肾293T细胞后,Western印迹检测其表达情况;将该重组质粒与ATG12表达质粒共转染293T细胞,通过免疫共沉淀法检测2个蛋白的相互作用。结果:Flag-ATG5真核表达质粒构建成功,转染293T细胞后融合蛋白获得表达,其相对分子质量约33×103;Flag-ATG5可与Myc-ATG12结合。结论:构建了带Flag标签的人ATG5真核表达载体,为进一步研究ATG5在自噬中的功能奠定了基础。     

含人抗体恒定区基因的酵母表达质粒的构建

本文主要报告了用以表达人-鼠嵌合抗体基因的酵母表达载体的构建、筛选与鉴定的研究结果.作者利用高度表达的酵母质粒YEP_(51),与含人抗体恒定区基因的pSV_2gptHuG_4两个质粒为材料,构建成可以供表达任何小鼠单克隆抗体的可变区基因,以构成嵌合的人-鼠抗体基因,用酶切回收插入DNA片段、原位和斑点杂交法对重组质粒予以鉴定和筛选,获得了pYEP-H重组的酵母表达载体.     

梅花鹿胸腺素beta10基因真核表达载体的构建及鉴定

转录组测序发现Tβ10在鹿茸中高表达,为了研究Tβ10与鹿茸生长发育间的关系,构建Tβ10真核表达载体。使用Trizol法提取梅花鹿鹿茸总RNA,PCR技术特异性扩增梅花鹿Tβ10基因,利用酶切位点将目的片段插入真核表达载体VR1012构建表达质粒,通过Fugene~?6将质粒瞬时转染到293T细胞中,使用Western blotting和免疫荧光方法检测目的基因的表达。结果发现克隆得到的梅花鹿Tβ10基因长度为129bp,编码42个氨基酸,成功构建真核表达载体VR1012-Tβ10-HA,转染后使用Western blotting方法检测到梅花鹿Tβ10在293T细胞中表达,免疫荧光方法证明梅花鹿Tβ10主要定位在细胞浆中。     

Vectors for the expression of PCR-amplified immunoglobulin variable domains with human constant regions.

Cassette vectors have been constructed for mammalian expression of complete immunoglobulin heavy and light chain genes whose variable regions are produced by the polymerase chain reaction (PCR). The light and heavy chain vectors have promoter, leader, partial intron, enhancer and constant region segments within modified pSV2-gpt and pSV2-neo plasmids, respectively. Variable (V) regions are obtained by PCR using a two step process: 1) the V gene is amplified from genomic or cDNA, cloned into an intermediate vector and sequenced; 2) the first PCR product serves as the template for a second amplification in which restriction enzyme recognition sites and limited flanking intron sequence are added. The second PCR product is inserted into the expression vector, which is then transfected into mouse myeloma cells. These vectors contain human constant regions and may be used to express chimeric, humanized or human Ig genes. This report describes the design of these vectors and their application for the expression of chimeric 60.3, an anti-CD18 antibody.     

Construction, expression, and biologic activity of murine/human chimeric antibodies with specificity for the human alpha/beta T cell receptor.

Murine/human chimeric antibodies with specificity for the human TCR-alpha/beta have been produced by genetic engineering. The L and H chain V region exons encoding the murine mAb BMA 031 were isolated and inserted into mammalian expression vectors containing the human kappa and gamma 1 or gamma 4 C region exons. The chimeric genes were transfected into murine Sp2/O hybridoma cells by electroporation and transfectomas secreting chimeric antibody were isolated. Secretion levels ranged from 1 to 7 pg/cell/24 h. The chimeric antibodies bound specifically to T cells and competed effectively with the parental murine mAb for binding to these sites. The ability to promote antibody-dependent cell-mediated cytolysis was significantly enhanced in the chimeric antibodies as compared with murine BMA 031. C-dependent cytolysis, however, was not detectable with any of the antibodies. Chimeric BMA 031 is a clinically relevant, genetically engineered antibody with potential uses in transplantation, graft-vs-host disease, autoimmune diseases and other T cell-related disorders.     

人尿激酶型纤溶酶原激活因子截短型突变体与绿色荧光蛋白在真核细胞HEK293F中的融合表达

目的:构建人尿激酶型纤溶酶原激活因子(uPA)截短型突变体与绿色荧光蛋白(EGFP)分泌型融合表达载体并在真核细胞中表达。方法:采用PCR法,分别以质粒pIRES2-EGFP和重组质粒pcDNA3.1(+)/uPA为模板,扩增出带BamHⅠ和XbaⅠ酶切位点的EGFP及带NheⅠ和HindⅢ酶切位点的uPA截短体基因片段,先后将EGFP和截短型uPA基因片段克隆到真核表达载体pcDNA3.1(+)上,转入HEK293F细胞,用G418对转染细胞进行加压筛选,通过共聚焦显微镜观察和ELISA方法鉴定表达产物。结果:DNA测序结果显示,uPA不同截短型突变体基因片段与EGFP基因融合的真核表达载体构建成功,共聚焦显微镜观察发现HEK293F细胞中有绿色荧光且定位于细胞质中,ELISA检测到HEK293F细胞培养上清中分泌型融合蛋白的表达。结论:构建了uPA截短型突变体与EGFP分泌型融合表达载体并在真核细胞中表达,为后期研究uPA的相互作用蛋白及其生理功能奠定了基础。     

人CD46 RNAi 逆转录病毒载体系统的构建与鉴定

目的:构建并筛选携带针对CD46基因的pSUPER retro RNAi逆转录病毒载体,从而特异、有效地抑制人CD46mRNA水平。方法:利用DNA重组技术,将2条60nt能转录产生靶向CD46小发夹RNA(shRNA)的寡核苷酸序列,定向克隆入逆转录病毒载体pSUPER retro,并转化大肠杆菌JM109。结果:重组载体经PCR及限制性内切酶酶切鉴定初步成功后送测序,结果表明序列正确。结论:特异性沉默CD46基因的pSUPER retro RNAi逆转录病毒载体构建成功,为后续转染Jurkat细胞,研究CD46在T细胞的信号转导中的作用奠定了基础,对进一步研究T细胞相关疾病及开展细胞免疫缺陷的治疗方面提供了新的思路与方向。     

miR-122过表达转基因小鼠质粒构建及其功能验证

目的:比较两种miR-122转基因小鼠过表达载体构建方法,为建立miR-122过表达转基因小鼠奠定基础。方法:PCR扩增长约291bp的pre-miR-122的序列,分别定向克隆到pBROAD3-GFP载体GFP基因上游内含子或下游3'UTR区域,两种质粒分别转染293T细胞,Q-PCR检测miR-122和GFP的表达水平,并观察GFP绿色荧光。miR-122 sensor reporter是将3个miR-122成熟序列的反义序列串联克隆至psiCHECK2载体luciferase 3'UTR中,然后分别与2种miR-122过表达质粒载体共转染293T细胞,最后检测荧光素酶活性来鉴定miR-122调控功能。结果:2种构建方法的miR-122表达水平都明显增高,而只有插入到GFP基因3'UTR的质粒表达GFP功能正常。结论:构建microRNA过表达载体时,microRNA位于报告基因3'UTR区域不会影响microRNA和报告基因的功能;构建的两种miR-122过表达质粒载体都可应用到转基因小鼠研究中,而将miR-122插入到GFP下游的方法则更利于miR-122的表达。     

Construction of recombinant murine retroviruses that express the human T-cell leukemia virus type II and human T-cell lymphotropic virus type III trans activator genes.

Recombinant retroviruses containing the trans activator genes of human T-cell leukemia virus (HTLV) type II and human T-cell lymphotropic virus type III were constructed. The trans activator genes tat II and tat III were inserted into the murine retroviral vector pZIPNEOSV(X)1. Recombinant plasmids were transfected into the psi 2 and psi AM packaging cell lines that produce murine leukemia virions containing no retroviral RNA. Functional tat II and tat III gene products were expressed as demonstrated by trans activation of HTLV type I and II and human T-cell lymphotropic virus type III long terminal repeat-directed gene expression in the respective infected cells. Use of these recombinant vectors permits high-efficiency gene transfer into a wide variety of cells, thereby providing the opportunity to study the biochemical effects associated with tat II and tat III gene expression.     

犬细小病毒VP2蛋白在真核细胞中的分泌表达及特性

摘要:【目的】利用真核细胞分泌表达犬细小病毒VP2蛋白和研究其特性。【方法】为构建犬细小病毒（Canine parvovirus, CPV）VP2基因的真核分泌型表达载体,首先通过酶切从含有人CD5信号肽序列的质粒中将CD5信号肽基因片段切出,将其连接到真核表达载体pcDNA3.1A的多克隆位点上,构建成pcDNA3.1-CD5sp质粒。然后再通过PCR方法从含有犬细小病毒VP2基因的质粒中扩增VP2基因,并将其插入到pcDNA3.1- CD5sp载体中CD5信号肽的下游,构建成VP2基因的真核分泌型表达载体pcDNA-CD5sp-VP2。经磷酸钙介导转染293T细胞,使其在真核细胞中进行分泌表达,并通过ELISA检测表达的VP2蛋白与犬转铁蛋白受体（TfR）结合的活性。【结果】序列分析结果表明,本实验构建的犬细小病毒VP2基因真核分泌型表达载体结构正确,将该表达载体转染的293T细胞,在培养基中通过Western-blot检测到有VP2重组蛋白的存在。经ELISA检测表明表达的重组VP2蛋白具有与犬转铁蛋白受体结合的活性。【结论】 利用人的CD5信号肽实现了犬细小病毒VP2蛋白在真核细胞中的分泌表达,表达的VP2蛋白具有与犬转铁蛋白受体结合的活性。     

白细胞介素-21与乙型肝炎病毒前S2S抗原融合蛋白在293T细胞中的表达

目的:构建白细胞介素-21(interleukin-21,IL-21)和乙型肝炎病毒前S2S抗原(S2S)的融合表达质粒,并研究其在293T细胞中的表达。方法:采用PCR方法扩增IL-21和HBV前S2S基因片段,分别克隆入pcDNA3真核表达质粒,用分子克隆方法构建融合表达质粒,并以脂质体2000转染293T细胞,分别应用ELISA法和Western Blot法检测细胞上清及细胞中IL-21和HBsAg的表达水平。结果:经酶切鉴定及DNA序列证实重组质粒内插入片段序列正确,三种重组质粒分别命名为pcDNA-IL-21、pcDNA-S2S和pcDNA-IL-21-S2S,并且重组质粒能在293T细胞内表达并分泌相关蛋白。结论:成功构建IL-21和乙型肝炎病毒前S2S抗原的融合表达质粒,重组质粒能在真核细胞内表达。     

人EYA基因家族的克隆、表达及转录活性分析

采用PCR方法从人组织或细胞cDNA文库中扩增Eya基因家族的完整编码序列,将所扩增的基因克隆到带FLAG标签的真核表达载体上,转染人胚肾293T细胞,Western blot鉴定Eya基因家族的表达。检测Eya基因及其与Six基因共转染对MEF3-Luc转录活性的影响。经限制性内切酶分析和DNA序列测定鉴定构建的重组表达载体正确,通过Western blot实验证明Eya基因家族真核表达载体构建成功。荧光素酶活性测定显示Eya能协同Six激活肌细胞生成素的表达。本研究进一步证实Eya是Six的转录共激活因子,能提高肌细胞增强因子的活性。     

Construction, expression and characterization of humanized antibodies directed against the human alpha/beta T cell receptor.

Completely humanized antibodies with specificity for the human alpha/beta TCR have been produced by genetic engineering. The L and H chain V region exons encoding the murine mAb BMA 031 CD regions and human EU framework regions were synthesized and replaced into previously isolated genomic fragments. These fragments were inserted into mammalian expression vectors containing the human kappa and gamma 1 C region exons. Two variants were constructed each containing selected BMA 031 amino acids within the human frameworks. The humanized genes were transfected into Sp2/0 hybridoma cells by electroporation and transfectomas secreting humanized antibody were isolated. Levels of antibody expression up to 7 pg/cell/24 h were obtained. The humanized antibody, BMA 031-EUCIV2, competed poorly with murine BMA 031 for binding to T cells. BMA 031-EUCIV3, however, bound specifically to T cells and competed effectively with both the murine BMA 031 antibody and a previously constructed chimeric BMA 031 antibody for binding to these cells. The relative affinity of BMA 031-EUCIV3 was about 2.5 times lower than BMA 031. The ability to promote antibody dependent cell-mediated cytolysis was significantly enhanced with the engineered antibodies as compared to murine BMA 031. Humanized BMA 031 is a clinically relevant, genetically engineered antibody with potential uses in transplantation, graft vs host disease, and autoimmunity.